{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03929120",
      "OrgStudyIdInfo": {
        "OrgStudyId": "18-007216"
      },
      "Organization": {
        "OrgFullName": "Mayo Clinic",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)",
      "OfficialTitle": "A Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients With Connective Tissue Disorders"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "November 5, 2019",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "April 24, 2019",
      "StudyFirstSubmitQCDate": "April 24, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 26, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 24, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 29, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Andy Abril, M.D.",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "Mayo Clinic"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Mayo Clinic",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Researchers are trying to find out more about the safety of a new treatment, Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) which is still experimental, for Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD)."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Interstitial Lung Disease",
          "Connective Tissue Diseases"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Interstitial Lung Disease with Connective Tissue Disorder",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Subjects with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD) will receive a new treatment called Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)",
            "InterventionDescription": "Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Interstitial Lung Disease with Connective Tissue Disorder"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Adverse Events",
            "PrimaryOutcomeDescription": "Number of adverse events reported with infusion of each intravenous Mesenchymal Stem Cells (MSC) dose",
            "PrimaryOutcomeTimeFrame": "6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAdults over 18 years of age and less than 80 years of age\nBoth female and male\nPatients with new diagnosis of interstitial lung disease associated with connective tissue disorders, Antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis or idiopathic pneumonia with autoimmune features (IPAF) or established diagnosis of ILD associated with CTD under conventional therapy for at least 6 months but less than 24 months, with no evidence of improvement.\nCompetent and able to provide written informed consent, and ability to comply with protocol\n\nExclusion Criteria:\n\nPatients with interstitial lung disease without evidence of a concomitant rheumatologic autoimmune disorder\nExposure to rituximab or cyclophosphamide on the previous 2 months\nSevere interstitial lung disease defined by the presence of severe hypoxemia at rest (SO2 < 88% at rest)\nClinical assessment that indicates active chronic infections such as osteomyelitis or active tuberculosis (TB), or acute infections such as pneumonia, active bronchitis, cellulitis, etc. or active solid tumors or hematologic malignancies\nPrevious treatment with mesenchymal stem cells\nClinically significant medical conditions within the six months before administration of BMD-MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient.\nMedical history of human immunodeficiency virus (HIV), Hepatitis B or C\nAbnormal complete blood count (CBC), creatinine, Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) at screening\nPregnant or breast feeding\nUnwilling to agree to use acceptable contraception methods during participation in the trial\nInability to provide informed consent",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Andy Abril, MD",
            "OverallOfficialAffiliation": "Mayo Clinic",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Mayo Clinic in Florida",
            "LocationCity": "Jacksonville",
            "LocationState": "Florida",
            "LocationZip": "32224",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Mayo Clinic Clinical Trials",
            "SeeAlsoLinkURL": "https://www.mayo.edu/research/clinical-trials"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008171",
            "ConditionMeshTerm": "Lung Diseases"
          },
          {
            "ConditionMeshId": "D000017563",
            "ConditionMeshTerm": "Lung Diseases, Interstitial"
          },
          {
            "ConditionMeshId": "D000003240",
            "ConditionMeshTerm": "Connective Tissue Diseases"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafAsFound": "Lung Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M5616",
            "ConditionBrowseLeafName": "Connective Tissue Diseases",
            "ConditionBrowseLeafAsFound": "Connective Tissue Diseases",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18965",
            "ConditionBrowseLeafName": "Lung Diseases, Interstitial",
            "ConditionBrowseLeafAsFound": "Interstitial Lung Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          }
        ]
      }
    }
  }
}